Biosynthetic Technologies Funding: How Much Did They Raise & Key Investors

How Much Did Biosynthetic Technologies Raise?
Funding & Key Investors

Biosynthetic Technologies has solidified its position in the sustainable chemical sector, securing a cumulative capital infusion of $52.2M. This trajectory of financial backing, punctuated by a recent strategic investment of $16.5M, underscores the market demand for high-performance, biobased alternatives to traditional petroleum-derived lubricants. By leveraging proprietary Estolide technology, the firm has successfully transitioned from early-stage development to a mature enterprise-level entity capable of scaling production for global industrial applications.

The company's growth narrative is defined by a series of strategic financing rounds that have enabled the refinement of its manufacturing processes. As the industry shifts toward ESG-compliant supply chains, Biosynthetic Technologies remains at the forefront of the transition, utilizing its recent capital injection to bolster its market presence and expand its reach into the personal care and metalworking fluid sectors.

What is Biosynthetic Technologies?

Biosynthetic Technologies

Manufacturing

Chemicals & Related Products

Biosynthetic Technologies specializes in the synthesis of high-performance base oils derived from organic fatty acids. Their core innovation, the Estolide molecule, provides a sustainable, biodegradable, and high-performance alternative to conventional synthetic lubricants. By ensuring compatibility with existing lubricant formulations, the company facilitates a seamless transition for manufacturers looking to improve their environmental footprint without compromising on technical efficacy. Their market position is anchored in the intersection of green chemistry and industrial utility, serving a diverse client base that spans the personal care, metalworking, and industrial lubricant industries.

How much funding has Biosynthetic Technologies raised?

Biosynthetic Technologies has raised a total of $52.2M across 4 funding rounds:

2012

Unspecified

$14.7M

2013

Unspecified

$9M

2014

Private Equity

$12M

2016

Debt

$16.5M

Unspecified (2012): $14.7M, investors not publicly disclosed

Unspecified (2013): $9M, investors not publicly disclosed

Private Equity (2014): $12M supported by Evonik

Debt (2016): $16.5M, investors not publicly disclosed

Key Investors in Biosynthetic Technologies

Evonik

Evonik Industries AG is a global leader in specialty chemicals, focusing on resource efficiency and performance materials to drive sustainable industrial innovation.

Undisclosed Investors

What's next for Biosynthetic Technologies?

With the support of its recent capital, Biosynthetic Technologies is poised to accelerate its commercialization strategy and deepen its penetration into high-growth industrial markets. The focus will likely shift toward optimizing supply chain efficiencies and scaling the production of Estolides to meet the increasing global demand for sustainable chemical solutions. As the company matures, it is expected to leverage its existing partnerships to further integrate its biobased compounds into mainstream industrial applications, effectively setting a new standard for performance and sustainability in the chemical manufacturing landscape.

See full Biosynthetic Technologies company page

See More Financial Insights